登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LIGHT】

LIGHT信息

英文名称:Tumor necrosis factor superfamily member 14
中文名称:肿瘤坏死因子超家族成员14
靶点别称:CD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
上市药物数量:0
临床药物数量:1
最高研发阶段:临床一期

LIGHT产品列表

 
评论(3)
LIT-H5242|Human LIGHT / TNFSF14 Protein, His Tag (active trimer) (MALS verified)
  1. +34XXXXXXX17
  2. 1人赞
  3. We use this protein as an ELISA standard. We are interested in quantifying soluble LIGHT concentration from human serum. This active form of the protein perfectly binds its receptors and policlonal antibodies. The standard curve obtained is highly reproducible. It was very easy to find all the information in the web of AcroBiosystems and to download the CoA, which was also very descriptive.
  4. 2021-10-12
LIT-H5269|Human LIGHT / TNFSF14 Protein, Fc Tag (active trimer) (MALS verified)
  1. 150XXXXXXX2
  2. 0人赞
  3. 购买蛋白用于ELISA检测,以及活性检测。acro的蛋白包装精美,还可以用来回收。蛋白质量也很好,用来做结合实验,曲线非常好。同时进行活性实验,结果显示蛋白活性很高,低浓度就能够引发下游的激活信号。
  4. 2022-11-14
LIT-H5269|Human LIGHT / TNFSF14 Protein, Fc Tag (active trimer) (MALS verified)
  1. 139XXXXXXX3
  2. 0人赞
  3. 百普赛斯的Human LIGHT / TNFSF14 Protein蛋白都很稳定,无论是细胞实验还是ELISA,表现都很好。支持
  4. 2022-11-07
 

LIGHT 分子别名

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

LIGHT 分子背景

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

LIGHT 前沿进展

LIGHT临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Quisovalimab CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 La Jolla Pharmaceutical Company, 协和发酵麒麟株式会社 详情
CBS-001 CBS-001 临床一期 Centessa Pharmaceuticals Plc 特发性肺纤维化, 炎性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定